Clinical aspects of adriamycin in Japan.

Recent Results Cancer Res

Published: December 1978

Adriamycin has not been as extensively evaluated in Japan as in some other countries. This is due both to the widespread use of mitomycin C and importantly to the alopecia caused by adriamycin being particularly disturbing to Japanese patients. Japanese studies have shown the drug to be highly active in tumors such as stomach cancer (31/92), lung cancer (27/84), and malignant lymphomas (15/46). Combination studies have been mainly with 5-FU although others have also been investigated. Other approaches which have been studied include intraarterial infusion, local application in bladder cancer, intrapleural application and in the treatment of childhood malignancies.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-81219-4_23DOI Listing

Publication Analysis

Top Keywords

clinical aspects
4
aspects adriamycin
4
adriamycin japan
4
japan adriamycin
4
adriamycin extensively
4
extensively evaluated
4
evaluated japan
4
japan countries
4
countries widespread
4
widespread mitomycin
4

Similar Publications

minimally invasive surgery is the surgery of the present and has become the "gold standard" for the most pathologies. The training of surgeons in minimally invasive techniques is mandatory required to be carried out during the residency program. In Romania, there is no national minimally invasive surgical training program, only universities and certain university hospitals are concerned with this aspect.

View Article and Find Full Text PDF

Introduction/aims: A previous randomized controlled trial showed that guided self-help acceptance and commitment therapy plus standard medical care (ACT+SMC) was superior to standard medical care alone (SMC) for improving quality of life (QoL) and mood at 9-weeks post randomization in a sample of people with muscle disorders (MD). This follow-up study evaluated whether these effects were maintained in the longer term alongside individual patterns of response.

Methods: The original study was a two-arm parallel group randomized controlled trial, which compared ACT+SMC to SMC.

View Article and Find Full Text PDF

Psychological evaluation of candidates for the uterus transplantation French trial.

Acta Obstet Gynecol Scand

December 2024

Department of Obstetrics, Gynecology and Reproductive Medicine, Foch Hospital, Suresnes, France.

Introduction: Since 2017, women with absolute uterine infertility due to Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome have been eligible to participate in a uterine transplantation clinical trial conducted by Foch Hospital in France. The aim of this study is to assess the psychological state of potential candidates, including recipients, their partners, and their living-related donors.

Material And Methods: Sixteen potential uterus transplant candidates, including recipients, partners, and living-related donors, participated in the study.

View Article and Find Full Text PDF

Objective: To characterize the public conversations around long COVID, as expressed through X (formerly Twitter) posts from May 2020 to April 2023.

Methods: Using X as the data source, we extracted tweets containing #long-covid, #long_covid, or "long covid," posted from May 2020 to April 2023. We then conducted an unsupervised deep learning analysis using Bidirectional Encoder Representations from Transformers (BERT).

View Article and Find Full Text PDF

Purpose: The relationship between sagittal lumbopelvic alignment and the bony pathomorphology of hip dysplasia is currently at the forefront of clinical and scientific interest. The aim of this study was to determine whether there is a compensatory lumbopelvic aspect associated with the two major acetabular phenotypes in dysplastic hips.

Methods: From September 2022 to March 2024, a total of 145 patients with symptomatic bilateral hip dysplasia were included in the study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!